EMA has recommended granting a marketing authorisation in the European Union (EU) for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF), two serious lung diseases that involve progressive and irreversible scarring (fibrosis) of the lung tissue.

There are limited treatment options for people suffering from IPF or PPF. Both conditions can cause severe symptoms, including difficulty breathing, leading to hospitalisation and ultimately death within a few years of diagnosis due to a progressive decline in lung function.

Jascayd has a different mechanism of action from authorised medicines for IPF and PPF and therefore represents a new treatment option for patients with these conditions. The active substance in Jascayd, nerandomilast, belongs to the class of PDE4 inhibitors and preferentially blocks the activity of an enzyme called PDE4B. This enzyme is expressed in the lungs and plays an important role in fibrosis…